These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37814439)

  • 1. Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats.
    Zhang J; Zhang C; Zhang T; Zhang L; Duan L
    J Neurogastroenterol Motil; 2023 Oct; 29(4):520-531. PubMed ID: 37814439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation.
    Zhang JD; Liu J; Zhu SW; Fang Y; Wang B; Jia Q; Hao HF; Kao JY; He QH; Song LJ; Liu F; Zhu BL; Owyang C; Duan LP
    Acta Pharmacol Sin; 2021 Nov; 42(11):1821-1833. PubMed ID: 33558654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.
    Zhuang X; Tian Z; Li L; Zeng Z; Chen M; Xiong L
    Front Microbiol; 2018; 9():1600. PubMed ID: 30090090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
    Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
    J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice.
    Zhang S; Hong G; Li G; Qian W; Jin Y; Hou X
    BMC Microbiol; 2023 Jan; 23(1):22. PubMed ID: 36658488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.
    Botschuijver S; Roeselers G; Levin E; Jonkers DM; Welting O; Heinsbroek SEM; de Weerd HH; Boekhout T; Fornai M; Masclee AA; Schuren FHJ; de Jonge WJ; Seppen J; van den Wijngaard RM
    Gastroenterology; 2017 Oct; 153(4):1026-1039. PubMed ID: 28624575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of altered gut microbiota on visceral hypersensitivity of postinfectious irritable bowel syndrome mice.
    Cheng F; Fan Z; Lin C; Zhu Y; He H; Dai N; Du L
    Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1220-1230. PubMed ID: 36165068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Gegen Qinlian Decoction on gut microbiota of irritable bowel syndrome with diarrhea rats].
    Zhang RQ; Fang ZA; Han WQ; Jing JQ; Liu Y; Yu B; Wang R; Sun M
    Zhongguo Zhong Yao Za Zhi; 2022 Dec; 47(24):6709-6719. PubMed ID: 36604921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach.
    Soldi S; Vasileiadis S; Uggeri F; Campanale M; Morelli L; Fogli MV; Calanni F; Grimaldi M; Gasbarrini A
    Clin Exp Gastroenterol; 2015; 8():309-25. PubMed ID: 26673000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity.
    Liu Z; Zhu S; He M; Li M; Wei H; Zhang L; Sun Q; Jia Q; Hu N; Fang Y; Song L; Zhou C; Tao H; Kao JY; Zhu H; Owyang C; Duan L
    Chin Med J (Engl); 2022 Jul; 135(14):1716-1727. PubMed ID: 36070467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electroacupuncture Relieves Irritable Bowel Syndrome by Regulating IL-18 and Gut Microbial Dysbiosis in a Trinitrobenzene Sulfonic Acid-Induced Post-Inflammatory Animal Model.
    Song YF; Pei LX; Chen L; Geng H; Yuan MQ; Xu WL; Wu J; Zhou JY; Sun JH
    Am J Chin Med; 2020; 48(1):77-90. PubMed ID: 31918565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome and gut microbiota.
    Canakis A; Haroon M; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):28-35. PubMed ID: 31789724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota Manipulation in Irritable Bowel Syndrome.
    Mazzawi T
    Microorganisms; 2022 Jun; 10(7):. PubMed ID: 35889051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients.
    Sun QH; Liu ZJ; Zhang L; Wei H; Song LJ; Zhu SW; He MB; Duan LP
    J Dig Dis; 2021 May; 22(5):246-255. PubMed ID: 33822477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome.
    Singh P; Lembo A
    Gastroenterol Clin North Am; 2021 Sep; 50(3):523-545. PubMed ID: 34304786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats.
    Yu ZC; Cen YX; Wu BH; Wei C; Xiong F; Li DF; Liu TT; Luo MH; Guo LL; Li YX; Wang LS; Wang JY; Yao J
    World J Gastroenterol; 2019 Aug; 25(29):3956-3971. PubMed ID: 31413530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines.
    Zhou Y; Zhang F; Mao L; Feng T; Wang K; Xu M; Lv B; Wang X
    Eur J Nutr; 2023 Feb; 62(1):139-155. PubMed ID: 35918555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.
    Chang C
    Clin Exp Gastroenterol; 2018; 11():335-345. PubMed ID: 30288076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.